LIUZHOU CITY, China, March 18, 2011 /PRNewswire-Asia/ -- China BCT Pharmacy Group, Inc., (OTC Bulletin Board: CNBI), ("China BCT" or the "Company"), a leading pharmaceutical distributor, retail pharmacy, and manufacturer of pharmaceutical products in Guangxi Province, China, today announced that its Form S-1 registration statement filed with the Securities and Exchange Commission ("SEC") was declared effective on March 17, 2011. Pursuant to the statement, a total of 5,630,575 shares have been registered with the SEC, representing approximately 13.98% of the Company's fully diluted shares outstanding as of February 28, 2011. The prospectus contained in the Form S-1 relates to the resale of shares issued to those stockholders who participated in previously completed private placement transactions which were exempt from the registration and prospectus delivery requirements of the Securities Act of 1933, as amended.
"With the effectiveness of our S-1 registration statement, China BCT has satisfied one of the criteria for upgrading to a senior exchange, which we are striving to accomplish in 2011," said Mr. Huitian Tang, Chairman and CEO of China BCT Pharmacy.
About China BCT
China BCT is engaged in pharmaceutical distribution, pharmacy retailing, and the manufacture of pharmaceuticals products through its subsidiaries Guangxi Liuzhou Baicaotang Medicine Limited, Hefeng Pharmaceutical Co. Limited, and Guangxi Liuzhou Baicaotang Medicine Retail Limited in Guangxi province, China. It operates a large regional retail network in Guangxi province, consisting of 187 directly owned retail stores in Guangxi province and currently over 8,000 products are distributed through the Company's wholesale distribution network. For more information, please visit www.china-bct.com .
Investor Relations Contact:
Ms. Shelly Zhang, Chief Financial Officer
CCG Investor Relations
China BCT Pharmacy Group, Inc.
Mr. Crocker Coulson, President
Tel: (86) 772-363-8318
Mr. Kalle Ahl, CFA, Account Manager
SOURCE China BCT Pharmacy Group, Inc.